<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>pharmacology and toxicology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>pharmacology and toxicology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="AlphaFold2 structures template ligand discovery
Authors: Lyu, J.; Kapolka, N.; Gumpper, R.; Alon, A.; Wang, L.; Jain, M.; Alvarez, X.; Sakamoto, K.; Kim, Y.; DiBerto, J.; Kim, K.; Tummino, T.; Huang, S.; Irwin, J.; Tarkhanova, O.; Moroz, Y.; Skiniotis, G.; Kruse, A.; Shoichet, B.; Roth, B.
Score: 53.2, Published: 2023-12-21 DOI: 10.1101/2023.12.20.572662
AlphaFold2 (AF2) and RosettaFold have greatly expanded the number of structures available for structure-based ligand discovery, even though retrospective studies have cast doubt on their direct usefulness for that goal.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/pharmacology-and-toxicology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="pharmacology and toxicology" />
<meta property="og:description" content="AlphaFold2 structures template ligand discovery
Authors: Lyu, J.; Kapolka, N.; Gumpper, R.; Alon, A.; Wang, L.; Jain, M.; Alvarez, X.; Sakamoto, K.; Kim, Y.; DiBerto, J.; Kim, K.; Tummino, T.; Huang, S.; Irwin, J.; Tarkhanova, O.; Moroz, Y.; Skiniotis, G.; Kruse, A.; Shoichet, B.; Roth, B.
Score: 53.2, Published: 2023-12-21 DOI: 10.1101/2023.12.20.572662
AlphaFold2 (AF2) and RosettaFold have greatly expanded the number of structures available for structure-based ligand discovery, even though retrospective studies have cast doubt on their direct usefulness for that goal." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/pharmacology-and-toxicology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-12-31T10:38:19+00:00" />
<meta property="article:modified_time" content="2023-12-31T10:38:19+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="pharmacology and toxicology"/>
<meta name="twitter:description" content="AlphaFold2 structures template ligand discovery
Authors: Lyu, J.; Kapolka, N.; Gumpper, R.; Alon, A.; Wang, L.; Jain, M.; Alvarez, X.; Sakamoto, K.; Kim, Y.; DiBerto, J.; Kim, K.; Tummino, T.; Huang, S.; Irwin, J.; Tarkhanova, O.; Moroz, Y.; Skiniotis, G.; Kruse, A.; Shoichet, B.; Roth, B.
Score: 53.2, Published: 2023-12-21 DOI: 10.1101/2023.12.20.572662
AlphaFold2 (AF2) and RosettaFold have greatly expanded the number of structures available for structure-based ligand discovery, even though retrospective studies have cast doubt on their direct usefulness for that goal."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "pharmacology and toxicology",
      "item": "https://trxiv.yorks0n.com/posts/pharmacology-and-toxicology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "pharmacology and toxicology",
  "name": "pharmacology and toxicology",
  "description": "AlphaFold2 structures template ligand discovery\nAuthors: Lyu, J.; Kapolka, N.; Gumpper, R.; Alon, A.; Wang, L.; Jain, M.; Alvarez, X.; Sakamoto, K.; Kim, Y.; DiBerto, J.; Kim, K.; Tummino, T.; Huang, S.; Irwin, J.; Tarkhanova, O.; Moroz, Y.; Skiniotis, G.; Kruse, A.; Shoichet, B.; Roth, B.\nScore: 53.2, Published: 2023-12-21 DOI: 10.1101/2023.12.20.572662\nAlphaFold2 (AF2) and RosettaFold have greatly expanded the number of structures available for structure-based ligand discovery, even though retrospective studies have cast doubt on their direct usefulness for that goal.",
  "keywords": [
    
  ],
  "articleBody": " AlphaFold2 structures template ligand discovery\nAuthors: Lyu, J.; Kapolka, N.; Gumpper, R.; Alon, A.; Wang, L.; Jain, M.; Alvarez, X.; Sakamoto, K.; Kim, Y.; DiBerto, J.; Kim, K.; Tummino, T.; Huang, S.; Irwin, J.; Tarkhanova, O.; Moroz, Y.; Skiniotis, G.; Kruse, A.; Shoichet, B.; Roth, B.\nScore: 53.2, Published: 2023-12-21 DOI: 10.1101/2023.12.20.572662\nAlphaFold2 (AF2) and RosettaFold have greatly expanded the number of structures available for structure-based ligand discovery, even though retrospective studies have cast doubt on their direct usefulness for that goal. Here, we tested unrefined AF2 models prospectively, comparing experimental hit-rates and affinities from large library docking against AF2 models vs the same screens targeting experimental structures of the same receptors. In retrospective docking screens against the {sigma}2 and the 5-HT2A receptors, the AF2 structures struggled to recapitulate ligands that we had previously found docking against the receptors experimental structures, consistent with published results. Prospective large library docking against the AF2 models, however, yielded similar hit rates for both receptors versus docking against experimentally-derived structures; hundreds of molecules were prioritized and tested against each model and each structure of each receptor. The success of the AF2 models was achieved despite differences in orthosteric pocket residue conformations for both targets versus the experimental structures. Intriguingly, against the 5-HT2A receptor the most potent, subtype-selective agonists were discovered via docking against the AF2 model, not the experimental structure. To understand this from a molecular perspective, a cryoEM structure was determined for one of the more potent and selective ligands to emerge from docking against the AF2 model of the 5-HT2A receptor. Our findings suggest that AF2 models may sample conformations that are relevant for ligand discovery, much extending the domain of applicability of structure-based ligand discovery.\nDiscovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships\nAuthors: Asquith, C. R. M.; East, M. P.; Laitinen, T.; Alamillo-Ferrer, C.; Hartikainen, E.; Wells, C. I.; Axtman, A. D.; Drewry, D. H.; Tizzard, G. J.; Poso, A.; Willson, T. M.; Johnson, G. L.\nScore: 1.2, Published: 2023-12-28 DOI: 10.1101/2023.12.28.573261\nThe oxindole scaffold has been the center of several kinase drug discovery programs, some of which have led to approved medicines. A series of two oxindole matched pairs from the literature were identified where TLK2 was a potent off-target kinase. The oxindole has long been considered a promiscuous inhibitor template, but across these 4 specific literature oxindoles TLK2 activity was consistent, while the kinome profile was radically different from narrow to broad spectrum coverage. We synthesized a large series of analogues and through quantitative structure-activity relationship (QSAR) analysis, water mapping of the kinase ATP binding sites, small-molecule x-ray structural analysis and kinome profiling, narrow spectrum, sub-family selective, chemical tool compounds were identified to enable elucidation of TLK2 biology.\nDrug promiscuity: problems and promises.\nAuthors: VanDongen, A. M.\nScore: 0.8, Published: 2023-12-30 DOI: 10.1101/2023.12.29.573633\nTherapeutic drugs exert their effect by binding to a specific target protein (receptor) and altering its activity. However, all drugs have undesirable side effects, which likely result from the drug binding to other protein targets. Drug promiscuity refers to the ability of small molecule compounds to bind with high affinity to multiple proteins. This drug property is responsible for the problems caused by their side effects. But drug promiscuity also presents a promise: if a drug targets numerous proteins, each interaction may contribute to its therapeutic efficacy. The ability to target multiple genes is especially promising for medicines that treat systemic diseases, including neurological disorders and cancers, which result from gene network problems. Here, I will review both aspects of drug promiscuity and illustrate a potential strategy to move this forward using a computer modeling approach.\n",
  "wordCount" : "611",
  "inLanguage": "en",
  "datePublished": "2023-12-31T10:38:19Z",
  "dateModified": "2023-12-31T10:38:19Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/pharmacology-and-toxicology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      pharmacology and toxicology
    </h1>
    <div class="post-meta">&lt;span&gt;updated on December 31, 2023&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.20.572662">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.20.572662" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.20.572662">
        <p class="paperTitle">AlphaFold2 structures template ligand discovery</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.20.572662" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.20.572662" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Lyu, J.; Kapolka, N.; Gumpper, R.; Alon, A.; Wang, L.; Jain, M.; Alvarez, X.; Sakamoto, K.; Kim, Y.; DiBerto, J.; Kim, K.; Tummino, T.; Huang, S.; Irwin, J.; Tarkhanova, O.; Moroz, Y.; Skiniotis, G.; Kruse, A.; Shoichet, B.; Roth, B.</p>
        <p class="info">Score: 53.2, Published: 2023-12-21 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.20.572662' target='https://doi.org/10.1101/2023.12.20.572662'> 10.1101/2023.12.20.572662</a></p>
        <p class="abstract">AlphaFold2 (AF2) and RosettaFold have greatly expanded the number of structures available for structure-based ligand discovery, even though retrospective studies have cast doubt on their direct usefulness for that goal. Here, we tested unrefined AF2 models prospectively, comparing experimental hit-rates and affinities from large library docking against AF2 models vs the same screens targeting experimental structures of the same receptors. In retrospective docking screens against the {sigma}2 and the 5-HT2A receptors, the AF2 structures struggled to recapitulate ligands that we had previously found docking against the receptors experimental structures, consistent with published results. Prospective large library docking against the AF2 models, however, yielded similar hit rates for both receptors versus docking against experimentally-derived structures; hundreds of molecules were prioritized and tested against each model and each structure of each receptor. The success of the AF2 models was achieved despite differences in orthosteric pocket residue conformations for both targets versus the experimental structures. Intriguingly, against the 5-HT2A receptor the most potent, subtype-selective agonists were discovered via docking against the AF2 model, not the experimental structure. To understand this from a molecular perspective, a cryoEM structure was determined for one of the more potent and selective ligands to emerge from docking against the AF2 model of the 5-HT2A receptor. Our findings suggest that AF2 models may sample conformations that are relevant for ligand discovery, much extending the domain of applicability of structure-based ligand discovery.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.28.573261">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.28.573261" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.28.573261">
        <p class="paperTitle">Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.28.573261" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.28.573261" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Asquith, C. R. M.; East, M. P.; Laitinen, T.; Alamillo-Ferrer, C.; Hartikainen, E.; Wells, C. I.; Axtman, A. D.; Drewry, D. H.; Tizzard, G. J.; Poso, A.; Willson, T. M.; Johnson, G. L.</p>
        <p class="info">Score: 1.2, Published: 2023-12-28 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.28.573261' target='https://doi.org/10.1101/2023.12.28.573261'> 10.1101/2023.12.28.573261</a></p>
        <p class="abstract">The oxindole scaffold has been the center of several kinase drug discovery programs, some of which have led to approved medicines. A series of two oxindole matched pairs from the literature were identified where TLK2 was a potent off-target kinase. The oxindole has long been considered a promiscuous inhibitor template, but across these 4 specific literature oxindoles TLK2 activity was consistent, while the kinome profile was radically different from narrow to broad spectrum coverage. We synthesized a large series of analogues and through quantitative structure-activity relationship (QSAR) analysis, water mapping of the kinase ATP binding sites, small-molecule x-ray structural analysis and kinome profiling, narrow spectrum, sub-family selective, chemical tool compounds were identified to enable elucidation of TLK2 biology.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.29.573633">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.29.573633" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.29.573633">
        <p class="paperTitle">Drug promiscuity: problems and promises.</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.29.573633" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.29.573633" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: VanDongen, A. M.</p>
        <p class="info">Score: 0.8, Published: 2023-12-30 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.29.573633' target='https://doi.org/10.1101/2023.12.29.573633'> 10.1101/2023.12.29.573633</a></p>
        <p class="abstract">Therapeutic drugs exert their effect by binding to a specific target protein (receptor) and altering its activity. However, all drugs have undesirable side effects, which likely result from the drug binding to other protein targets. Drug promiscuity refers to the ability of small molecule compounds to bind with high affinity to multiple proteins. This drug property is responsible for the problems caused by their side effects. But drug promiscuity also presents a promise: if a drug targets numerous proteins, each interaction may contribute to its therapeutic efficacy. The ability to target multiple genes is especially promising for medicines that treat systemic diseases, including neurological disorders and cancers, which result from gene network problems. Here, I will review both aspects of drug promiscuity and illustrate a potential strategy to move this forward using a computer modeling approach.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
